Although some 40 years have passed since type I diabetes was first defined, its cause remains unknown. The autoimmunity paradigm of immune dysregulation has not offered an explanation for its rising incidence, nor means of preventing it, and there is arguably good reason to consider alternatives. The accelerator hypothesis is a singular, unifying concept that argues that type I and type II diabetes are the same disorder of insulin resistance, set against different genetic backgrounds. The hypothesis does not deny the role of autoimmuniy, only its primacy in the process. It distinguishes type I and type II diabetes only by tempo, the faster tempo reflecting the more susceptible genotype and (inevitably) earlier presentation. Insulin resistance is closely related to the rise in overweight and obesity, a trend that the hypothesis deems central to the rising incidence of all diabetes in the developed and developing world. Rather than overlap between the two types of diabetes, the accelerator hypothesis envisages overlayFeach a subset of the general population differing from each other only by genotype. Indeed, it views type I and type II diabetes as a continuum, where the infinitely variable interaction between insulin resistance and genetic response determines the age at which b-cell loss becomes critical. Adult diabetes is not viewed as an entity, but rather as diabetes presenting in adulthood. Childhood diabetes, similarly, is diabetes presenting in childhood. The increasing incidence of both is primarily the result of lifestyle change and the rise in body weight that has resulted
The Issue
Diabetes is of two types. Type I is an autoimmune disorder of childhood, characterized by thinness, acute onset, ketoacidosis and insulin dependency. Type II is a metabolic disorder of middle-life, usually associated with corpulence, slow in onset and non-insulin-dependent.
These definitions are the basis on which a generation or more has understood the disease of diabetes, but they need urgent revision. More than half of patients with type I diabetes present in adulthood, 1 when their onset is slow, and many neither develop acidosis nor require insulin for many years. Type II diabetes now occurs in children, 2 sometimes with keto-acidosis, 3 and insulin dependency frequently ensues given time. Although a difference in body weight still remains, there is otherwise little more than tempo to distinguish the two. Accurate classification depends on a proper understanding of mechanisms, and is important because it guides both treatment and prevention. Commentators have begun to question the existing classification of diabetes, because it seems poorly adapted to the changing characteristics of the disease. 4, 5 As a recent editorial explained, a classification may come to embody outworn concepts that prevent us from seeking or applying new informationyestablished classification may perversely serve to discourage new thinking, and when a classification is questioned, so too must be the mechanisms on which it is based. 4 The accelerator hypothesis is a singular, unifying theory that attempts to establish a common basis for type I and type II diabetes. First published in 2001, 6 it is now supported in whole, [7] [8] [9] [10] [11] or in part, 12 by six independent clinical studies, has been the subject of three editorials [13] [14] [15] and has more than 100 citations in the literature. The hypothesis argues that type I and type II diabetes are the same disorder of insulin resistance set against different genetic backgrounds. In doing so, it questions not so much a place for autoimmunity in type I diabetes, 16 but its primacy in causation. The hypothesis is felt to be important because an understanding of the mechanisms responsible for type I diabetes is needed to devise effective means of preventing it. Presently, we do not have that understanding, nor the means of prevention. The aim of this review is to explore the mechanisms on which the current classification, and with it the current understanding of diabetes, are based and to suggest an alternative that may better explain its changing character. It focuses on a single themeFthat of tempoFas the factor that may unify diabetes. Tempo, it argues, is related to insulin resistance, which, in turn, is closely linked to overweight and obesity. Evidence is presented to suggest that islet-related autoimmunity, for so long the hallmark of type I diabetes, is a physiological response to upregulation of the b-cell, and for that reason is found increasingly among patients with type II diabetes. Diabetes, of whatever type, is ultimately a disorder of b-cell failure, and the accelerator hypothesis centres on the tempo of b-cell loss to explain the commonality between type I and type II.
The hypothesis is not without its detractors, and the editorials in particular offer a useful perspective as to how far opinion leaders in the field feel that the available evidence justifies such a fundamental shift in thinking. [13] [14] [15] Adjustment is part of hypothesis building, and the aim of this commentary is to update the evidence and to review the hypothesis in the light of the critiques that it has received.
The Setting
Until 40 or so years ago, diabetes was regarded as a single disorder. Himsworth had commented in the 1930s on an insulin-resistant individual who required larger doses of insulin, but the designations of adult onset and juvenile onset were descriptive and unrelated to any perceived differences in mechanism. In the mid-1960s, the Belgian histopathologist Willy Gepts 17 first described infiltration of lymphocytes in the islets of children who died within a few days of developing diabetes. He noted similarities to struma lymphomatosa of the thyroid, first described by Hashimoto in 1912, but regarded by the late 1950s as 'autoimmune' because of the antibodies to thyroglobulin found in the serum of such patients. In 1974, Jorn Nerup et al. 18 described an association between childhood diabetes and the immune response or HLA genes on the short arm of chromosome 6, and in the same year, Franco Bottazzo and Deborah Doniach 19 famously reported the presence of antibodies to the islet cells in blood samples from people with insulindependent diabetes. Together, lymphocytic infiltration of the islets, immunogenetic linkage and autoantibodies specific to the b-cell prompted a radical revision in the understanding of diabetes. The prevailing model of diabetes as a single disorder that could present either in childhood (juvenile onset) or later in life (adult onset) was replaced by a classification that clearly distinguished type I diabetes from type II diabetes (then almost exclusively a disorder of later adulthood). Type I became known as autoimmune diabetes, caused by a dysregulated immune system that attacked, and ultimately destroyed, the b-cells. Type II was a metabolic disorder driven by the demands of insulin resistance.
The past four decades have seen a progressive rise in the incidence of diabetes. The focus has been on type II diabetes, because of its greater numbers and clinical impact, but the pattern has been identical for type I. 20, 21 Although type II diabetes is widely understood to be linked to obesity and the insulin resistance it causes, 22,23 the rise in type I has not been satisfactorily explained. Meanwhile, the incidence of obesity has tripled, and the concept of systemic inflammation as fundamental to metabolic disturbance has emerged. 24 Fat accumulation, most specifically visceral fat, attracts macrophages whose pro-inflammatory cytokines are believed to reduce the sensitivity of tissues to insulin. 25 Indeed, to complement the accelerator hypothesis for type I diabetes, it has been suggested that type II diabetes may be an immune disorder. [26] [27] [28] It seems likely, as we shall see, that type I and type II diabetes sit at opposite ends of a spectrum, along which the contributions of inflammation and insulin resistance to b-cell failure vary inversely.
The central concept: tempo
Diabetes develops only when the b-cells are unable to produce sufficient insulin for the body's needs. The deficiency might be supply-led, as in the monogenic disorders HNF-1a and Kir-6, where there is a primary deficiency in insulin supply, 29, 30 or demand-led, as in the case of insulin resistance. Both may contribute, and probably do in most instances. Besides obesity, factors such as puberty, pregnancy, chronic infection, physical inactivity, endocrine disorders, even polluted air 31 can stress the b-cell, but all appear to act through a loss of insulin sensitivity. A measure of b-cell mass, adjusted for insulin sensitivity, describes the functional reserve of the b-cells.
Reserve decreases progressively over time through natural apoptosis, but for most the decline is slow and unimportant because it does not become critical over a lifetime. In others, the tempo is quicker and the loss of b-cells relative to demand results first in glucose intolerance and then in diabetes ( Figure 1) . Crucially, the age at which diabetes develops is linked not so much to the cause of b-cell loss as to the tempo of b-cell loss. Whether slow (no diabetes), moderate (diabetes in adulthood) or rapid (diabetes in childhood), the concept is the same. Age at onset, incidence and, ultimately, prevalence are all determined by tempo. The concept of tempo is continuous and avoids a need for categorization.
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The driver: insulin resistance Apart from rare monogenic forms, genes do not cause diabetes. They fix the level of susceptibility to a given environmental risk. The accelerator hypothesis envisages an infinitely variable interaction between insulin resistance (the driver) and genotype (the modulator). The interaction determines the probability of disease. Thus, environmental risk and genetic susceptibility each contributes a proportion to the probability of developing diabetes. Figure 2 illustrates the relationship between infinitely variable risk, susceptibility and probability. People with low susceptibility may tolerate substantial insulin resistance without b-cell failure, reflected in the clinical observation that only a minority of the most obese are diabetic. On the other hand, the most susceptibleFthose carrying particular HLA (immune response) genesFneed little environmental pressure to lose critical b-cell function. Some 2-3% of the population carry the most susceptible genotype, but only 10-20% of them (as we will see later, selectively those of higher body mass index (BMI)) develop type I diabetes. Susceptibility will reflect not only the response of b-cell to rising load but also intrinsic variation in b-cell reserve, which may be genetic or programmed during early life. The recently described TNF2L7 gene may be an example of intrinsic b-cell impairment. 32 Insulin resistance is acquired largely, though not exclusively, from excess weight gain and physical inactivity. It accelerates the rate of b-cell apoptosis through glucotoxicity and lipotoxicity, 33, 34 and accounts for what has traditionally been termed type II diabetes. However, as the environmental pressure from insulin resistance has grown, so has the tempo of b-cell loss quickened, and the age at presentation correspondingly fallen. What was diabetes in adulthood has become diabetes in childhood. People with type II diabetes are part of the general population, but a growing proportion of it as obesity and with it insulin resistanceFrises. Although birth weight no longer appears to predict insulin resistance later in childhood, 35 as was the case in past generations, a correlation between insulin resistance and body mass is apparent from an early age, 35 and strengthens as children grow older. 36 For conceptual purposes, people with type I and II diabetes have often been viewed as members of separate populations, allowing a degree of overlap between them to account for the type II patient who progresses to insulin dependency ('type 1 Insulin resistance G e n e t ic s u s c e p t ib il it y Probability % Figure 2 Depiction of the probability of developing diabetes as a function of an infinitely variable relationship between insulin resistance (the driver) and genetic susceptibility to it (the modulator).
The accelerator hypothesis TJ Wilkin however, are in reality as much members of the general population as those who develop type II, exposed to the same obesogenic environment and demands on the b-cell. People with type I diabetes merely represent extreme susceptibility, where insulin resistance is met by an intense immune response to metabolically upregulated islets. Islet-related autoimmunity is widely viewed as the result of immune dysregulation, but the accelerator hypothesis considers it as a physiological and predictable response to b-cell upregulation among immunoreactive, but otherwise normal, individuals. That is not to dismiss its contribution, whereby the inflammation associated with the autoimmune response further accelerates the tempo of b-cell loss and diabetes onset.
Insulin dependency is the end stage towards which all cases of diabetes move, and the notions of type I and type II, as insulin-and non-insulin-requiring, may be artificial. Dependency on insulin for glucose control is just a matter of time, and tempo is the only attribute that distinguishes one 'type' from another. Without insulin resistance, 'autoimmune' diabetes would not occur, and backwards regression of the gradient that describes the rise in type I diabetes over recent years flattens out in the 1950s, 38 a point in time after the World War II when the environmental changes associated with the rise in diabetes arguably began. Insulin resistance is associated with visceral fat mass, and is widely believed to explain the epidemic rise of type II diabetes in the industrially developed and developing world. 39 The accelerator hypothesis argues that visceral weight gain is also central to type I diabetes, as much as it is responsible for its rising incidence as for that of type II, and the environmental factor in type I diabetes that has eluded epidemiology for so long. The concept of an aetiological link between the two types of diabetes is not new, and has been suggested before by the author, 40 but the evidence is now stronger.
Type I diabetes is the same as type II except for one essential variable, that is, the intensity of the immune response to metabolically upregulated islets.
Immune tolerance
How does the hypothesis cope with the issue of immune tolerance? Tolerance is conventionally regarded as absolute, and autoimmunity as a pathological abrogation of it. However, the author has argued, 41 like others before him, 42 that the immune system evolved originally as a 'housekeeper', which is programmed to phagocytose the detritus of natural cell death. It retains that primordial function. From this perspective, 'autoimmunity' will be antigen-driven and specific, its intensity responsive to the rate of apoptosis (antigenic load) and modulated by genetic influences. Selftolerance and its abrogation are not at an issue where clones expand appropriately to remove apoptotic bodies. Antibodies in this context are classic immunological adaptors. They link the specific subparticulate molecules to be cleared to non-specific Fc receptors of phagocytic neutrophils, which in turn engulf the complex and dispose of it through the reticuloendothelial system. 43 At its most intense, the reaction recruits T cells, which are pro-inflammatory and directly destructive. It has long been recognized that islet cells are both metabolically and immunogenically upregulated when functionally stressed by a rising blood glucose. 44, 45 At whatever age it emerges, insulin resistance could be expected to increase b-cell stress and to intensify an immune response in those who are genetically predisposed. The phenomenon of insulin resistance which, as the response to progressively rising body weight, appears to have been largely responsible for reducing the age at presentation of type II diabetes over recent times, might be doing just the same for type I diabetes by promoting the immunological accelerants of b-cell death in a progressively younger age group. Furthermore, if immune responsiveness is a variable across the population, 'autoimmunity' should not be confined to type I diabetes (although of course it will always be, if used to define type I diabetes). If nowadays there is little clinically to distinguish two types of diabetes, there is little fundamentally either.
Three phases of diabetes
The natural history of type II diabetes recognizes three phases: (a) euglycaemia with hyperinsulinaemia (prediabetes), (B) hyperglycaemia with hyperinsulinaemia (non-insulin-dependent diabetes) and (C) hyperglycaemia with hypoinsulinaemia (insulin-dependent diabetes). Any critic of the accelerator hypothesis would want to ensure that the natural history of type I diabetes, although accelerated, went through the same stages as that of type II. The tempo of type II diabetes can be so slow that phase A may last decades, and a clinical diagnosis delayed well into phase B. A generation ago, when type II diabetes was typically a disorder of middle age and beyond, many died before phase C (insulin dependency) was reached. In contrast, a substantial proportion of young people with type II diabetes now require insulin as a result of accelerated b-cell failure and earlier onset of disease.
The same three phases can be identified in type I diabetes, although their relative durations may be different (Figure 3) . Islet-related autoantibodies can often be detected many years before diagnosis, yet recent studies make it clear that pretype I diabetes is an insulin-resistant state, characterized by hyperinsulinaemia. [46] [47] [48] [49] Predictions and the evidence to support them A hypotheses make predictions, and the test of its legitimacy is the evidence to support them. The accelerator hypothesis makes a number of intuitive predictions, and the evidence is summarized below.
1. An association should exist between the rising incidence of type I diabetes and a rise in body mass (surrogate for insulin resistance). Although a lot of attention has been paid in recent years to the earlier presentation and increasing frequency of type II diabetes, less notice has been taken of the parallel trend in type I, though it is no less striking. 53 There has been a progressive rise in the incidence of type I diabetes since the 1950s, 21 and a tripling during the past generation. Although a rise in obesity which parallels that of diabetes is essential for the hypothesis, it is not sufficient. Parallel trends are poor evidence of association, let alone of causality.
2. Children who develop type I diabetes should be heavier before onset than their peers who do not. Again, associative (crosssectional) studies cannot prove causality, but temporal sequence can be of help in longitudinal studies. The rule of temporality requires that cause precede effect, and that there be an identifiable interval between them. There are several studies reporting that children who develop type I diabetes in childhood were heavier in infancy than their peers who do not, the earliest reaching back to the 1970s. [54] [55] [56] [57] [58] The
Childhood Diabetes in Finland Study Group reports that a relative weight in childhood of 4120% is associated with a more than two-fold greater risk of future type I diabetes. 58 3. The heavier child should develop diabetes at a younger ageFtrue acceleration. Although direction of causality will always remain uncertain in the absence of controlled intervention, it seems unreasonable to attribute weight gain to earlier diabetes when clinical observation suggests the reverse. It is important in this regard not to confound the greater body mass of children who develop type I diabetes with the temporary loss of body mass that precedes it. To show a link between body mass and age at onset within a group of diabetic children would refine the argument to one of true acceleration, for it would imply a quantitative relationship between the two among individuals, not merely their co-existence in a population. There are now six fulllength reports of independent cohorts from the United Kingdom, Germany, Austria, the United States and Australia, where age at onset of type I diabetes was inversely related to BMI (Figure 4 ). [7] [8] [9] [10] [11] [12] The first of these also analyzed boys and girls separately. Gender differences in age at presentation of diabetes disappeared after adjusting for BMI, suggesting that body massFor something closely related to it (for example, insulin resistance)Fwas responsible. 7 The second study was able to
show that those children who were the heaviest (and The accelerator hypothesis TJ Wilkin youngest) at presentation were also the heaviest up to 10 years before diagnosis. 8 It has been suggested that acceleration of tempo will not necessarily mean greater lifetime risk of type I disease, and there are a number of epidemiological studies reporting that lifetime risk of type I diabetes has not changed with acceleration of onset. 59, 60 Apparent lack of change in lifetime risk, however, may yet reflect increasing difficulty in the classification of diabetes. Acceleration of tempo and progressive convergence of the diabetic phenotypes (see later) together anticipate an increase in diabetes at all ages. 4. As the risk of type I diabetes rises, the proportion of its probability attributable to susceptibility should fall. As intimated earlier, the probability of developing a multifactorial disorder such as type I diabetes has two componentsFenvironmental risk and genetic susceptibility. Crucially, both are proportions, and a rise in one must result in a fall of the other. There is compelling evidence that the genetic contribution to type I diabetes is falling as the environmental contribution is rising. The FinnDiane Study Group compared the proportions of high-risk {(DR3) -DQA1*05-DQB1*02; (DR4) -DQB1*0302; (DR3)-DQA1*05-DQB1* 02/DRB1*0401-DQB1*0302} and protective {(DR15) -DQB1* 0602; (DR1301) -DQB1*0603} HLA haplotypes in unselected children who developed type I diabetes during the periods 1939-1965 and 1990-2001 . 61 High-risk alleles gave place over time to protective alleles, from which the authors concluded that 'ythe need for genetic susceptibility to develop type 1 diabetes has decreased over time, owing to an increasing environmental pressure'. A second study confirmed these findings in an independent cohort concluding that they were 'yconsistent with the hypothesis that the rise in type I diabetes is due to a major environmental effect. 62 The progressive rise in BMI at diagnosis of type I diabetes in children over the past 20 years, and its correlation with age at onset among individuals (doseresponse), is consistent with body mass being the environmental risk responsible. 8, 9 5. It should be possible to show directly that those at risk who go on to develop type I diabetes are more insulin resistant than those who do not. Direct evidence is now emerging that those who develop type I diabetes are more insulin resistant than those who do not. 63, 64 Fourlanos and colleagues compared the insulin resistance of 43 at-risk subjects who progressed to type I diabetes over a median observation period of 4 years with that of 61 subjects who did not, and concluded that insulin resistance is an independent risk factor for progression to clinical type I diabetes in individuals with islet autoimmunity. 48 Rate of progression is a measure of tempo, and the only variable independently associated with progression was insulin resistance. 47 Some intriguing data from identical twin studies also indicate that the co-twin who goes on to develop type I diabetes is more insulin resistant, with poorer b-cell function, than the co-twin who does not. 49 6. The phenotypes of children with type I and type II diabetes will ultimately converge as the contribution made by the genetic difference between them declines. The hypothesis asserts that type I and type II diabetes are the same disease of b-cell loss, but for the genes that control its tempo. As the role of immune response genes declinesFas the only factor to distinguish type I from type II diabetes fadesFthe hypothesis predicts that their phenotypes will converge. The rising dominance of environmental risk (obesity, insulin resistance) over genetic susceptibility would anticipate an ever-younger population of diabetic children who are overweight and seropositive for islet-related antibodies.
Although the immuno-responsive HLA DR3/DR4 child will never escape the obesogenic environment of his peers, s/he will always be expected to rank among the youngest at presentation (the 'spring harvest' 65 ). The phenotype of the type I diabetic has changed progressively from the wasted, dehydrated and pre-comatose child to one of normal or excess weight, and difficulty with the clinical classification of childhood diabetes is already an issue in paediatric clinics. Indeed, the BMI at presentation of British children with type I diabetes was already exceeding that of their age-matched peers by the mid-1990s ( Figure 5 ). 8 Convergence of the phenotype is not limited to children, nor indeed to those with established diabetes. The features that traditionally distinguish type I from type II diabetes (autoimmunity and insulin resistance, respectively) appear to be admixed in the first-degree relatives of patients with type I diabetes, 66 and autoimmunity in adults with type II diabetes was noted long ago. 67 The immune profiles of children with type I and type II diabetes are also (predictably) converging. 68, 69 As the insulin-resistant phenotype begins to dominate, so the b-cells become more antigenic, and the less reactive HLA genes gain penetrance. A study by Gilliam et al. 70 reported islet-related autoantibodies in 89% of diabetic 8-to 18-year olds with mixed phenotype at presentation and in 33% of those who were typically type II. An earlier publication from the same group also reported cellular immune responses to islet-related proteins in children presenting with typical type II phenotype. 71 It may be no accident that autoantibodies to insulin, and particularly to proinsulin, are the first to appear in children who subsequently develop diabetes, 72 because the circulating levels of insulin and pro-insulin rise exponentially with insulin resistanceFnor that autoantibodies to GAD (glutamic acid decarboxylase) and IA-2 (protein tyrosine phosphatase) follow, because both are antibodies to cellular enzymes whose expression is increased when the b-cell is upregulated.
Limitations and challenges
The accelerator hypothesis may be criticized for failing to address the wealth of animal evidence cited in support of autoimmunityFbut it does not do so dismissively. The BB rat, NOD mouse and other models suggest that the immune system can spontaneously cause b-cell disease and diabetes.
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The pathways involved have been teased apart meticulously, and the immunological processes described in detail. However, the issue for the hypothesis is not so much whether a dysregulated immune system can destroy the b-cell mass (which clearly it can), but whether the process described in inbred rodents under pathogen-free conditions necessarily relates to outbred humans. A number of studies have emerged since the hypothesis was first published that challenge it wholly or in part. The first, from Birmingham, UK, was unable to confirm the key prediction of an inverse correlation between BMI and age at onset population in a cohort of type I diabetic children. 73 Nevertheless, all of the six other studies cited in this review were larger, measured body weight after rehydration and refeeding, and were able to show this correlation. [7] [8] [9] [10] [11] The study by Dabelea et al. 12 reported (the predicted) inverse relationship between age at diabetes onset and BMI, but only among children whose fasting C-peptide levels lay below the median, not above it. The difference was interpreted to mean that any relationship to insulin resistance applied only to a subset of type I diabetic children with low b-cell reserve. The one adjustment that was not made, however, may have been the crucial oneFthe HLA genotype. Those children who obeyed the prediction were younger than those who did not. The younger the diabetic child at diagnosis, the more likely he/she is to carry higher susceptibility HLA genes, 74 and so it is possible, even probable, that the proportion of children carrying high susceptibility HLA genes was greater -and the rate of progression to diabetes faster -in the younger group than it was in the older group. Bingley et al. 75 raised a similar objection, based on data from the European Nicotinamide Diabetes Intervention Study (ENDIT), which was of equally short duration. We have responded to both the above findings that the accelerator hypothesis is based on the long-term (20 þ years) observation of whole populations with type I diabetes comprising slow as well as fast progressors. 76, 77 The much briefer periods analyzed by Dabelea and Bingley may have prejudiced their own findings by favouring faster to the exclusion of slower progressors.
The recently discovered TCF7L2 gene appears to reduce b-cell function, and is associated with an odds ratio of 1.36 for type II diabetes among adults. 78 Field et al. 79 genotyped 6200 type I diabetic children under the age of 17 years for the TCF7L2 gene, and rejected the accelerator hypothesis because they found no difference in the gene's frequency from normal controls. However, the premise was flawed. An environmental pressure that converts susceptibility into disease will select the most susceptible first, and only the most susceptible (HLA DR3/4) would be expected to succumb in childhood, irrespective of TCF7L2. 80 Indeed, TCF7L2 is associated with diabetes only later in life for the very reason that it confers less susceptibility than HLA. The same group performed a similar analysis with the FTO gene, which is associated with a small increase in body mass and segregates with type II diabetes in adulthood. 81 Again, they found no evidence for its association with type I diabetes, but FTO is only weakly associated with weight gain in children and its contribution to diabetes in children, wherein only small differences in weight (for many different reasons) are needed because susceptibility is at its highest, may be undetectable. 84 none has been confirmed and, apart from body mass, none shows correlations within type I diabetic populations to suggest the dose responsiveness needed to satisfy cause and effect. The prevalence of obesity has trebled over the past generation. Insulin resistance, resulting from a combination of obesity and physical inactivity, is a serious candidate for the 'elusive' environmental factor responsible for the rising incidence of type I diabetes and, as such, is a true accelerator. At its simplest, the accelerator hypothesis can be reduced to the unfavourable interplay of two variables: insulin sensitivity and b-cell reserve. Tempo, and tempo alone it is argued, defines a continuum for what in the past has been categorized. The three phases in progression to insulin dependency can all be identified in both types of diabetes, differing only (although sometimes substantially) in their relative duration. Not to take account of these phases and their differences in tempo will make it conceptually difficult to regard as equivalent two diabetic states where insulin appears to be needed from the outset in one, but only (if ever) after a long period of clinical diabetes in the other. The requirement for insulin in both cases is nevertheless reached at corresponding points in the progression. All people with diabetes move towards this point of insulin-dependencyFsome reach it rapidly, others perhaps not in a lifetime.
A hypothesis postulating body mass as a primary risk factor in the aetiology of type I, as well as type II, diabetes is novel, but eminently testable. Ultimately, it will be necessary to establish whether strategies to reduce insulin resistance in those at risk from type I diabetes, through lifestyle change, metformin or one of the thiazolidinediones, 85 is paralleled by a deceleration in immune damage to the b-cells and by the slowing of conversion from risk to disease. There is ample evidence that insulin re-sensitization is a highly effective decelerator of progression to type II diabetes in the adult at risk. 86, 87 The notion that type I could represent merely the accelerated development of type II diabetes is important if it implies that strategies currently on trial to suppress the immunological accelerator of type I diabetes (for example, anti-CD3 88, 89 ) leave unchanged the insulin resistance that provoked it. Of course, intervention that reduces the immune response may be expected to reduce the tempo of type I diabetes, as was the case years ago with cyclosporine, 90 but the control of weight gain further upstream, and with it insulin resistance, could be a more fundamental, safer and cheaper means of avoiding diabetes. 91 
Conclusion
Until recently, the interpretation of diabetes used to be straightforward. There was a childhood type that required insulin and an adult type that did not. Adult-onset diabetes seldom presented before the age of 50 years, and most died with it rather than of it. Childhood diabetes presented acutely and could be life-threatening. The adult diabetic was overweight, and the child underweight. This picture of contrasts has changed dramatically over the course of a single generation to one of a spectrum, and the driver, according to accelerator hypothesis, is insulin resistance attributable largely to the increase in childhood obesity. Diabetes is now more common, it presents at an earlier age, many adults require insulin and many children do not. Such has been the convergence in phenotype of the young diabetic that the current system of classification finds it increasingly difficult to distinguish the childhood diabetic as type I or type II. Classifications are important in formulating appropriate treatment and in directing effective prevention.
The current classification of diabetes may need changing, and the accelerator hypothesis offers a structure on which such a change might be based. The ultimate test of the hypothesis will be a randomized trial, where insulin sensitization is the intervention, and conversion from risk to disease is the outcome measure. Anything that reduces childhood obesity, the hypothesis predicts, will reduce childhood diabetesFtype I and type II.
Key evidence for the accelerator hypothesis K The rise in incidence of type I diabetes has been contemporaneous with the rise in childhood obesity (parallel trends) 21, 53 K Children who go on to develop type I diabetes are heavier as toddlers than their peers who do not (time-lagged association, where cause precedes effect) [54] [55] [56] [57] [58] K In populations of children with type I diabetes, the fattest present youngest (true acceleration, and the only example of 'dose-response' among the many candidate triggers for type I diabetes) [7] [8] [9] [10] [11] [12] K The contribution of high susceptibility genes to the development of type I diabetes has diminished over the past generation, consistent with the rising contribution of environmental pressure 61, 62 K Insulin resistance precedes the onset of type I diabetes, 46, 47 and among children at risk, those with the highest insulin resistance at baseline are those most likely to develop type I diabetes 48 K In twins at genetic risk of type I diabetes, those who go on to develop disease have higher insulin resistance and lower b-cell reserve than those who do not 49 The accelerator hypothesis TJ Wilkin
